Juvenile rheumatoid arthritis : Juvenile rheumatoid arthritis, also known as juvenile idiopathic arthritis, is the most common type of arthritis in children under the age of 16. Juvenile rheumatoid arthritis causes persistent joint pain, swelling and stiffness. Some children may experience symptoms for only a few months, while others have symptoms for the rest of their lives.
The major emphasis of treatment is to help the child regain normal level of physical and social activities. This is accomplished with the use of physical therapy, pain management strategies and social support. Another emphasis of treatment is to control inflammation as well as extra-articular symptoms quickly. Doing so should help to reduce joint damage, and other symptoms, which will, help reduce levels of permanent damage leading to disability. Most children are treated with non-steroidal anti-inflammatory drugs and intra-articular corticosteroid injections. Methotrexate, a disease modifying anti-rheumatic drug (DMARD) is a powerful drug which helps suppress joint inflammation in the majority of JIA patients with polyarthritis (though less useful in systemic arthritis).Newer drugs have been developed recently, such as TNF alpha blockers, such as etanercept
Juvenile rheumatoid arthritis : Juvenile rheumatoid arthritis, also known as juvenile idiopathic arthritis, is the most common type of arthritis in children under the age of 16. Juvenile rheumatoid arthritis causes persistent joint pain, swelling and stiffness. Some children may experience symptoms for only a few months, while others have symptoms for the rest of their lives.
The major emphasis of treatment is to help the child regain normal level of physical and social activities. This is accomplished with the use of physical therapy, pain management strategies and social support. Another emphasis of treatment is to control inflammation as well as extra-articular symptoms quickly. Doing so should help to reduce joint damage, and other symptoms, which will, help reduce levels of permanent damage leading to disability. Most children are treated with non-steroidal anti-inflammatory drugs and intra-articular corticosteroid injections. Methotrexate, a disease modifying anti-rheumatic drug (DMARD) is a powerful drug which helps suppress joint inflammation in the majority of JIA patients with polyarthritis (though less useful in systemic arthritis).Newer drugs have been developed recently, such as TNF alpha blockers, such as etanercept